The systemic pharmacology of XFZYD in the prevention of atherosclerotic cardiovascular disease (ASCVD) has shown that the mechanism of XFZYD is mainly reflected in the protection of vascular endothelium, prevention of oxidative stress, and inhibition of inflammation; the effective component quercetin was also shown to protect injured endothelial cells and reduce the endothelial inflammatory response (ICAM-1, VCAM-1, and TNF-α) induced by LPS in vitro [47]. Here, VCAM1 is linked to atherosclerosis.